FREQ News and Press, Frequency Therapeutics Inc. From 07/02/21

Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will pr...

Frequency Therapeutics, Inc., (Nasdaq: FREQ) today shared a statement from David L. Lucchino, Frequency’s Chief Executive Officer, in support of the Hearing Loss Association of America (HLAA) and its efforts to advance the voice of the patient in leading the first-ever Externally...

Frequency Therapeutics (FREQ): Q1 GAAP EPS of -$0.60 misses by $0.88.Revenue of $4.7M (-35.3% Y/Y) misses by $3.43M.Shares -0.79% PM.Press Release For further details see: Frequency Therapeutics EPS misses by $0.88, misses on revenue

Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss), Further Clarify Acquired Sensorineural Hearing Loss Target Patient Populations and Future Study Design Company Anticipates Initiation of New FX-322 Phas...

Biotech companies are about the riskiest investment someone can find in the stock market. They are often small, cash-strapped, and have a future inextricably tied to the success or failure of one clinical trial. For every Amgen , which has gone from a market cap of less than $1 bill...

I previously covered Frequency Therapeutics after the company had initiated a Phase 2a trial on the heels of a positive Phase 1/2 trial. This Phase 2a trial featured about three times more patients but failed to show the same promising efficacy in a recent data read-out. Managemen...

Frequency Therapeutics (NASDAQ: FREQ) is a clinical-stage biotech company currently conducting multiple clinical trials on FX-322, a hearing loss drug that is notably Frequency's only product in clinical development. Although final phase 2a results have yet to be released, interim r...

Company Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington University Medical School in St. Louis Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will pr...